Pancreatic cancer 'dream team' tackles baffling, deadly disease

April 7, 2014

UC San Francisco has been selected to join a national "dream team" on pancreatic cancer, part of a project designed to accelerate treatment and discoveries for one of the most deadly forms of cancer.

The team will be announced on April 7, 2013 during the annual meeting of the American Association for Cancer Research.

The fourth leading cause of cancer death in the United States, according to the National Cancer Institute, progress in treating has long been hobbled by a difficulty at detecting it early and by a poor response to therapies by patients. While it is relatively rare, it now kills nearly as many as breast cancer and only about six percent of those diagnosed with it live as long as five years.

The goal of the dream team is to turn pancreatic cancer into a treatable disease.

Margaret Tempero, MD, a UCSF professor of medicine and director of the UCSF Pancreas Center, will lead the UCSF portion of the research. A pioneer in applying radioactively tagged antibodies and accelerating other cancer therapies, Tempero is known internationally for her efforts to improve the care of patients with pancreatic cancer.

In the dream team project, Tempero and UCSF colleagues will collaborate nationally studying vaccines and other immune-based strategies to keep pancreatic cancer in check. The dream team will be funded over three years by an $8 million grant sponsored by Stand Up To Cancer (SU2C), the Lustgarten Foundation, and the Fox Family Cancer Research Funding Trust, along with the American Association for Cancer Research, SU2C's scientific partner.

"We are starting to make real progress, this is the beginning of a new era for pancreatic cancer," said Tempero who has been involved with research into the disease for 30 years. "The cellular makeup of pancreatic tumors is unique from other cancers, which is partly why pancreatic cancer is such a difficult disease. However, we are beginning to see some very gratifying responses to treatment—and now through surgery and chemotherapy, patients have a much better chance than they did just a decade ago. With its targeted approach, the dream team project will help us move forward in battling this very challenging disease."

UCSF has special expertise in combatting and treating pancreatic cancer.

In one recent discovery reported in February in the journal Nature Cell Biology, researchers led by Matthias Hebrok, PhD, head of the UCSF Diabetes Center, reported the identification in mice of a key gene that normally holds tumor development at bay, but when damaged by mutation, allows to develop.

In 2012, UCSF launched a multi-disciplinary, patient-centered Pancreas Center designed to advance the care of patients with pancreatic diseases through prevention, early detection, research and treatment. The center's team includes specialists in medical oncology, gastroenterology, surgery, nursing, psychology and radiology for the diagnosis and treatment of disease and the management of pain.

Compared to other cancers, pancreatic cancer is relatively rare, representing less than 3 percent of all new cases in the United States, but it is particularly lethal. It becomes more common as people age, and occurs slightly more often in men than women.

An estimated 45,000 people in the U.S. were diagnosed with it last year, and more than 38,000 people died from it, reported the National Cancer Institute.

Tempero has served as the founding deputy director of the UCSF Helen Diller Family Comprehensive Cancer Center and as chief of medical oncology in the Department of Medicine. She was president in 2004 of the American Society of Clinical Oncology, the world's largest organization for clinical oncologists. In February, she was named editor in chief of the Journal of the National Comprehensive Cancer Network. She has authored or co-authored more than 100 peer-reviewed articles, two books and 30 book chapters. She is currently a member of the board of directors for the Association of Northern California Oncologists as well as a member of the Scientific Advisory Board for the Pancreatic Cancer Action Network and the V Foundation.

Joining her from UCSF are:

Andrew Ko, MD, associate professor of clinical medicine; Pamela Munster, MD, professor of medicine and director of the UCSF Early Phase Clinical Trials Unit; Michael Korn, MD, associate professor of medicine; Lawrence Fong, MD, associate professor of medicine; Eric Collisson, MD, assistant professor of medicine; Pam Elmore, MA, research coordinator; Elizabeth Dito, RN; Julie Sudduth-Klinger, protocol project manager; and Jennifer Luan, lead clinical research coordinator.

Altogether, eight other institutions are represented on the team: Johns Hopkins University; Abramson Cancer Center of the University of Pennsylvania; Washington University in St. Louis; Oregon Health & Science University; New York University Langone Medical Center; Stanford University; University of Cambridge; and Memorial Sloan Kettering Cancer Center.

The project will be led by Elizabeth M. Jaffee, MD, professor of oncology at the Johns Hopkins University School of Medicine; and Robert H. Vonderheide, MD, DPhil, associate director for translational research at the Abramson Cancer Center.

Explore further: Pancreatic cancer surgery findings presented at SSO

Related Stories

Pancreatic cancer surgery findings presented at SSO

March 13, 2014
Despite the benefits of surgery for early stage pancreatic cancer, it remains under-utilized for patients with this deadly disease, according to a new national analysis of trends and outcomes. Physician-scientists at University ...

Screen some patients with acute pancreatitis for pancreatic cancer, researchers suggest

February 26, 2014
In a study published in Clinical Gastroenterology and Hepatology, Saint Louis University researchers have found a link between acute pancreatitis (inflammation of the pancreas) and pancreatic cancer, a finding which may eventually ...

New findings show link between diabetes and pancreatic cancer

March 14, 2014
In a new study published today in Annals of Surgical Oncology, clinicians worked with mathematicians to review data from 1973 to 2013 to conclude there was a time-dependent link between being diagnosed with diabetes and pancreatic ...

Cell-surface receptor offers promising breakthrough for pancreatic cancer patients

April 3, 2014
Pancreatic cancer rates in the U.S. have been rising over the past decade, and the disease takes a very heavy toll. The American Cancer Society estimates that in the last year alone about 45,220 people were diagnosed with ...

Gene identified in increasing pancreatic cancer risk

December 29, 2011
Mutations in the ATM gene may increase the hereditary risk for pancreatic cancer, according to data published in Cancer Discovery, the newest journal of the American Association for Cancer Research.

Swedish test may boost pancreatic cancer survival rates

March 18, 2014
Swedish researchers have developed a new method for diagnosing pancreatic cancer at a much earlier stage than currently possible, the University of Gothenburg said Tuesday.

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.